Prion disease is a group of rare, always-fatal brain disorders caused by a normal protein in the body that misfolds into a toxic shape and triggers a chain reaction of damage. It affects roughly 1 to 2 people per million each year. Unlike infections caused by bacteria or viruses, prion diseases are caused by a protein alone, with no DNA or RNA involved, making them unlike any other type of disease in medicine.
How a Single Protein Destroys the Brain
Your brain naturally produces a protein called PrP, which sits on the surface of nerve cells. In its normal form, this protein is harmless. But when PrP misfolds into an abnormal shape, it becomes sticky, clumps together, and recruits neighboring normal proteins to misfold as well. This cascade spreads through the brain like falling dominoes.
The misfolding begins when two key structural regions of the protein detach from each other. Normally, these regions are locked together by a set of molecular bonds that act like gatekeepers, holding the protein in its correct shape. When those bonds break, whether through a genetic mutation, random chance, or exposure to an already-misfolded protein, the structure destabilizes. The protein loses some of its spiral shape, exposes parts that are usually hidden, and becomes prone to clumping into insoluble deposits.
As these misfolded proteins accumulate, they punch tiny holes in brain tissue, giving it a sponge-like appearance under a microscope. This is why prion diseases are sometimes called spongiform encephalopathies. The damage is irreversible. Neurons die, brain function deteriorates, and the disease progresses relentlessly.
Three Ways Prion Disease Starts
Prion diseases fall into three categories based on how they originate: sporadic, genetic, and acquired.
- Sporadic: The vast majority of cases. The protein misfolds for no identifiable reason. This is how most cases of Creutzfeldt-Jakob disease (CJD) begin, typically in people over 60.
- Genetic: Inherited mutations in the PRNP gene, which provides the blueprint for making the prion protein, cause the protein to be more prone to misfolding. Some mutations change a single building block in the protein. Others insert extra segments or produce an abnormally short version. These mutations lead to familial CJD, Gerstmann-Sträussler-Scheinker syndrome, and fatal familial insomnia.
- Acquired: Exposure to misfolded prions from an outside source. This is the rarest route and includes variant CJD (linked to contaminated beef), kuru (historically transmitted through ritualistic cannibalism in Papua New Guinea), and iatrogenic cases from medical procedures.
Types of Human Prion Disease
The most common human prion disease is classic Creutzfeldt-Jakob disease. It accounts for the large majority of cases, strikes older adults, and progresses rapidly. Once symptoms appear, most people die within a year.
Variant CJD is a separate disease linked to eating beef from cattle infected with bovine spongiform encephalopathy, commonly known as mad cow disease. It was first identified in the United Kingdom in 1996, about a decade after people are believed to have consumed contaminated food. That delay is typical of prion diseases, which can incubate silently for years or even decades before symptoms emerge. Unlike classic CJD, variant CJD often strikes people in their 20s or younger and causes distinctive symptoms including pain from light touch.
Fatal familial insomnia is an inherited prion disease that progressively destroys the brain’s ability to sleep. Gerstmann-Sträussler-Scheinker syndrome, also inherited, causes slowly worsening problems with coordination and movement, typically over several years rather than months. Rarer forms include sporadic fatal insomnia and variably protease-sensitive prionopathy.
Symptoms and How the Disease Progresses
The earliest signs of prion disease are often subtle and easy to mistake for other conditions. In classic CJD, the most common initial symptoms include rapidly worsening memory problems, confusion, personality changes, and difficulty with coordination or walking. Vision problems, muscle jerks, and stiffness can follow. What sets prion disease apart from other forms of dementia is the speed. Alzheimer’s disease unfolds over years. CJD can take someone from the first sign of trouble to complete inability to function within a few months.
As the disease advances, people lose the ability to speak, move, and eventually swallow. The final stages involve a state of unresponsiveness. Because the brain damage is widespread and irreversible, the decline does not plateau or improve.
Variant CJD tends to start with psychiatric symptoms, including depression, anxiety, and withdrawal, before neurological signs develop. The total course of illness is somewhat longer, often lasting 12 to 14 months.
How Prion Disease Is Diagnosed
Diagnosis has historically been difficult because definitive confirmation required examining brain tissue after death. That has changed with the development of a lab test called RT-QuIC, which detects tiny amounts of misfolded prion protein in cerebrospinal fluid (the fluid surrounding the brain and spinal cord) or samples from the nasal lining.
The test works by mixing a patient’s sample with normal prion protein in a lab dish. If misfolded prions are present, they trigger the same chain reaction of misfolding that happens in the brain, and the resulting clumps can be measured. In a large prospective study, RT-QuIC performed on cerebrospinal fluid achieved 96% sensitivity and 100% specificity. When combined with a nasal sample, those numbers reached 100% on both counts. This means the test almost never misses a true case and virtually never produces a false positive.
Brain MRI also plays a key role. Specific patterns of signal abnormality on MRI, particularly in certain deep brain structures, can strongly suggest CJD and help distinguish it from other causes of rapid cognitive decline.
Medical Transmission and Contamination Risks
Prion diseases are not contagious through casual contact, airborne droplets, or sexual transmission. However, prions are extraordinarily resistant to standard sterilization methods. They survive autoclaving, chemical disinfection, and even incineration at temperatures that would destroy bacteria and viruses.
More than 500 cases of iatrogenic (medically transmitted) CJD have been documented worldwide. The majority were traced to human growth hormone extracted from the pituitary glands of deceased donors (a practice discontinued in the mid-1980s) and dura mater grafts, a type of tissue used in brain surgery. Smaller numbers of cases have been linked to corneal transplants, contaminated neurosurgical instruments, and brain electrodes used in diagnostic procedures. Modern safeguards, including synthetic growth hormone and strict surgical protocols for suspected cases, have made new iatrogenic transmission extremely rare.
Treatment and Experimental Therapies
There is currently no cure for any prion disease, and no approved treatment can slow its progression. Care focuses on managing symptoms and keeping the person as comfortable as possible.
The most promising experimental approach targets the problem at its source: reducing the amount of prion protein the brain makes in the first place. If there is less normal protein available, there is less raw material for the misfolding chain reaction. In March 2025, the FDA cleared a clinical trial called PRiSM, which is testing a small interfering RNA molecule designed to cut the genetic instructions for making prion protein before it is ever produced. The phase 1 trial is enrolling 15 symptomatic patients who each receive a single dose delivered by lumbar puncture, with later patients receiving larger doses. A separate observational group of 15 patients receives no treatment, providing a comparison.
This is the second active clinical trial for prion disease. The first, launched in 2023 by a pharmaceutical company, is testing a different molecule with a similar goal of lowering prion protein levels. Researchers are also exploring gene editing and epigenetic approaches that could potentially silence the PRNP gene more permanently.
These trials represent a significant shift. For decades, prion disease was considered so rare and so rapidly fatal that drug development received little attention. The current wave of research has been driven in part by Sonia Vallabh, a scientist at the Broad Institute who discovered she carries the mutation for fatal familial insomnia and redirected her career toward finding a treatment before symptoms begin.